Importance of genetics in acute myeloid leukemia
DOI:
https://doi.org/10.23938/ASSN.0327Palabras clave:
Acute myeloid leukemia. Genetic marker. Mutation. Whole-genome sequencing. Prognosis.Resumen
Acute myeloid leukemia (AML) comprises a biologically and clinically heterogeneous group of aggressive disorders that occur as a consequence of a wide variety of genetic and epigenetic abnormalities in hematopoietic progenitors. Despite significant advances in the understanding of the biology of AML, most patients will die from relapsed disease. Whole-genome studies have identified novel recurrent gene mutations with prognostic impact in AML; furthermore, it is likely that in the near future genome-wide sequencing will become a routine for newly diagnosed patients with AML. Therefore, future clinical trials should aim to identify genetically defined high-risk patients, and further research is necessary to identify effective agents and develop new individualized therapeutic strategies for the treatment of this deadly disease.
Descargas
Citas
1. RAVANDI F, CORTES J, FADERL S, O'BRIEN S, GARCIA-MANERO G, VERSTOVSEK S et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 2010; 116: 5818-5823.
https://doi.org/10.1182/blood-2010-07-296392
2. BURNETT AK. Treatment of acute myeloid leukemia: are we making progress? Hematology Am Soc Hematol Educ Program 2012; 1-6.
https://doi.org/10.1182/asheducation.V2012.1.1.3797038
3. POWELL BL, MOSER B, STOCK W, GALLAGHER RE, WILLMAN CL, STONE RM et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116: 3751-3757.
https://doi.org/10.1182/blood-2010-02-269621
4. PATEL JP, LEVINE RL. How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia? Hematology Am Soc Hematol Educ Program 2012; 28-34.
https://doi.org/10.1182/asheducation.V2012.1.28.3797923
5. SCHLENK RF, DOHNER K, KRAUTER J, FROHLING S, CORBACIOGLU A, BULLINGER L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918.
https://doi.org/10.1056/NEJMoa074306
6. VARDIMAN JW, THIELE J, ARBER DA, BRUNNING RD, BOROWITZ MJ, PORWIT A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
https://doi.org/10.1182/blood-2009-03-209262
7. DOHNER H, ESTEY EH, AMADORI S, APPELBAUM FR, BUCHNER T, BURNETT AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
https://doi.org/10.1182/blood-2009-07-235358
8. DING L, LEY TJ, LARSON DE, MILLER CA, KOBOLDT DC, WELCH JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.
https://doi.org/10.1038/nature10738
9. STIREWALT DL, RADICH JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650-665.
https://doi.org/10.1038/nrc1169
10. WEISBERG E, BARRETT R, LIU Q, STONE R, GRAY N, GRIFFIN JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 2009; 12: 81-89.
https://doi.org/10.1016/j.drup.2009.04.001
11. PARK IK, MISHRA A, CHANDLER J, WHITMAN SP, MARCUCCI G, CALIGIURI MA. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Blood 2013; 121: 2064-2073.
https://doi.org/10.1182/blood-2012-07-444018
12. GALE RE, GREEN C, ALLEN C, MEAD AJ, BURNETT AK, HILLS RK et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776-2784.
https://doi.org/10.1182/blood-2007-08-109090
13. PRATCORONA M, BRUNET S, NOMDEDEU J, RIBERA JM, TORMO M, DUARTE R et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 2013; 121: 2734-2738.
https://doi.org/10.1182/blood-2012-06-431122
14. PATEL JP, GONEN M, FIGUEROA ME, FERNANDEZ H, SUN Z, RACEVSKIS J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089.
https://doi.org/10.1056/NEJMoa1112304
15. ESTEY E. High cytogenetic or molecular genetic risk acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2010; 474-480.
https://doi.org/10.1182/asheducation-2010.1.474
16. WELCH JS, LINK DC. Genomics of AML: clinical applications of next-generation sequencing. Hematology Am Soc Hematol Educ Program 2011; 30-35.
https://doi.org/10.1182/asheducation-2011.1.30
17. Cancer Genome Atlas Research Network. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N Engl J Med 2013; 368: 2059-2074.
https://doi.org/10.1056/NEJMoa1301689
18. KVINLAUG BT, CHAN WI, BULLINGER L, RAMASWAMI M, SEARS C, FOSTER D et al. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res 2011; 71: 4117-4129.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-CompartirIgual 4.0.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
